



Divi's Laboratories Limited

Date.31st January 2015

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza
Bandra-Kurla Complex, Bandra (East)
MUMBAI – 400 051

Fax Nos.022 – 2659 8237 / 38

Dear Sir,

Sub: Un-audited financial results for the quarter and nine months ended 31st December 2014 and Limited Review report –reg

Ref: Clause 41 of Listing Agreement - Stock code: DIVISLAB


Pursuant to Clause 41 of the Listing Agreement, please find enclosed un-audited financial results along with the limited review report for the third quarter ended 31st December, 2014.

Above un-audited financials were approved and taken on record by the Board of Directors of the Company at their meeting held on Saturday, 31st January, 2015.

The Company proposes release of press note as per the enclosed format. This is for your information and records. Kindly acknowledge the receipt of the same.

Thanking You,

Yours faithfully,
For Divi's Laboratories Limited


P V Lakshmi Rajani
Company Secretary
(ACS 18882)

“An ISO-9001, ISO-14001 and OHSAS-18001 Triple certified company”

Regd. Off : Divi Towers, 7-1-77/E/1/303, Dharam Karan Road, Ameerpet, Hyderabad - 500 016. INDIA
CIN : L24110TG1990PLC011854 Tel : 91-40-2378 6300, Fax : 91-40-2378 6460

E-mail : mail@divislaboratories.com, Website : www.divislaboratories.com



DIVI'S LABORATORIES LIMITED

UN-AUDITED FINANCIAL RESULTS (STANDALONE)
FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2014

PART-I

(Rs.in Lakhs)

	Particulars	STANDALONE					
		Quarter ended			Nine Months ended		Year Ended
		31.12.2014	30.09.2014	31.12.2013	31.12.2014	31.12.2013	31.03.2014
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
(1)	(2)	(3)	(4)	(5)	(6)	(7)	
1	Income from operations	78808	82977	68741	225761	176917	250718
	(a) Net Sales/Income from operations (Net of Excise Duty)						
	(b) Other Operating Income	304	337	186	931	420	679
	Total Income from operations (net)	79112	83314	68927	226692	177337	251397
2	Expenses						
	a. Cost of materials consumed	34672	41097	24473	105441	81011	103189
	b. Purchases of stock-in-trade		0	0		0	0
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(2808)	(6040)	1151	(13626)	(19622)	(11375)
	d. Employee benefits expense	7459	6948	5710	20425	16628	22543
	e. Depreciation and amortization expense	2879	2926	2327	9131	6667	9206
	f. Other Expenses	11080	10629	8814	31546	25417	35154
	Total Expenses	53282	55560	42475	152917	110101	158717
3	Profit from Operations before Other Income, Finance Costs & Exceptional Items (1-2)	25830	27754	26452	73775	67236	92680
4	Other Income	1994	1554	791	4817	9253	8390
5	Profit from ordinary activities before finance costs & exceptional Items (3+4)	27824	29308	27243	78592	76489	101070
6	Finance Costs	48	43	35	127	115	206
7	Profit from ordinary activities after finance costs but before exceptional Items (5-6)	27776	29265	27208	78465	76374	100864
8	Exceptional items	0	0	0	0	0	0
9	Profit from ordinary activities before Tax (7-8)	27776	29265	27208	78465	76374	100864
10	Tax Expense	5718	6301	5306	16650	16508	21692
11	Net Profit from ordinary activities after Tax (9-10)	22058	22964	21902	61815	59866	79172
12	Extra-ordinary items (net of tax expense)	0	0	0	0	0	0
13	Net Profit (+)/Loss(-) for the period (11-12)	22058	22964	21902	61815	59866	79172
14	Share of profit / (loss) of associates	0	0	0	0	0	0
15	Minority Interest	0	0	0	0	0	0

16	Net Profit (+)/Loss(-) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)	22058	22964	21902	61815	59866	79172
17	Paid-up Equity Share Capital (Face Value : Rs.2 per share)	2655	2655	2655	2655	2655	2655
18	Reserves excluding revaluation reserves as per balance sheet of previous accounting year						300787
19.i	Earnings per Share (before extraordinary items) (of Rs.2/- each) (not annualized):						
	a) Basic	16.62	17.30	16.50	46.57	45.10	59.65
	b) Diluted	16.62	17.30	16.50	46.57	45.10	59.65
19.ii	Earnings per Share (after extraordinary items) (of Rs.2/- each) (not annualized):						
	a) Basic	16.62	17.30	16.50	46.57	45.10	59.65
	b) Diluted	16.62	17.30	16.50	46.57	45.10	59.65


PART-II - SELECT INFORMATION FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2014

A	PARTICULARS OF SHAREHOLDING						
1	Public shareholding - No. of shares - Percentage of shareholding	63603674 47.92%	63603674 47.92%	63556194 47.88%	63603674 47.92%	63556194 47.88%	63603674 47.92%
2	Promoters and promoter group shareholding a) pledged / encumbered b) non-encumbered: - No. of shares - Percentage of shares (as a % of the total shareholding of the promoter group) - Percentage of shares (as a % of the total share capital of the company)	Nil 69130616 100% 52.08%	Nil 69130616 100% 52.08%	Nil 69178096 100% 52.12%	Nil 69130616 100% 52.08%	Nil 69178096 100% 52.12%	Nil 69130616 100% 52.08%


	Particulars	Quarter ended 31-12-2014
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	13
	Disposed off during the quarter	13
	Remaining unresolved at the end of the quarter	Nil

NOTES:

1. The above results for the quarter ended 31st December 2014, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 31st January, 2015 and were subjected to 'limited review' by the Auditors.
2. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 notified under the Companies Act, 1956.
3. As per Clause 41 of the listing agreement, the company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end.



(Handwritten signature)




4. Details of forex gain/loss are given below:

Particulars	Quarter ended			Nine Months ended		Year Ended
	31.12.2014	30.09.2014	31.12.2013	31.12.2014	31.12.2013	31.03.2014
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Forex Gain/(Loss)	1116	432	(534)	1683	6842	5042


Forex gain has been included in Other Income and forex loss has been included in Other Expenses.

5. As per the requirements of the Companies Act, 2013 ("the Act"), the company has computed depreciation on the basis of the estimated economic lives or useful lives of fixed assets in the manner prescribed in Schedule II of the Act. Consequently, depreciation for the quarter ended 31st December, 2014 is higher by ₹ 60 lakhs and ₹ 765 lakhs for the 9 months ended 31st December, 2014. Depreciation of ₹ 1051 lakhs (net of deferred tax) on account of assets whose useful life is already exhausted as on 1st April 2014 has been adjusted to Retained Earnings.
6. Figures for the previous year/period have been regrouped or reclassified, wherever necessary.

Place: Hyderabad
Date: 31-01-2015




for Divi's Laboratories Limited


Dr. Murali K. Divi
Chairman & Managing Director

*This is the statement referred to in our
Limited Review Report dt 31-01-2015*

N. S. Rao



DIVI'S LABORATORIES LIMITED
Hyderabad

PRESS RELEASE dated 31st January, 2015


Divi's Labs earns a PAT of Rs.221 crores in Q3/FY15

Divi's Laboratories has earned a Profit after Tax (PAT) of Rs.221 crores on a total income of Rs.791 crores, on a stand-alone basis, for the quarter ended 31st December, 2014. For the corresponding quarter of the last year the company earned a PAT of Rs.219 crores on a total income of Rs. 689 crores.

Forex gain for the current quarter amounted to Rs.11 crores while there was a forex loss of Rs.5 crores during the corresponding quarter last year. The company has capitalized fixed assets aggregating to Rs.143 crores during the current quarter.

The company's operations were affected for a brief period during October, 2014 on account of HUDHUD cyclone at Visakhapatnam.

For the 9-month period ended 31st December, 2014, the company earned a total income of Rs.2267 crores as compared to Rs. 1773 crores during the corresponding 9-month period of last year. PBT for the current 9-month period came to Rs.785 crores as against a PBT of Rs. 764 crores for the previous period. PAT for the current 9-months is Rs.618 crores as against Rs.599 crores for the previous period.





P.V.R.K. Nageswara Rao & Co.,
Chartered Accountants

LIMITED REVIEW REPORT

TO
THE BOARD OF DIRECTORS OF
DIVI'S LABORATORIES LIMITED


We have reviewed the accompanying statement of standalone unaudited financial results of **DIVI'S LABORATORIES LIMITED** for the quarter and nine months ended **31st December, 2014** except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors / Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the accounting standards issued under the Companies (Accounting Standard) Rules, 2006 which continue to apply as per Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014, and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P.V.R.K. NAGESWARA RAO & Co.,
Chartered Accountants
Firm's Registration Number: 002283S


N. ANKA RAO
Partner
Membership Number: 23939



HYDERABAD
31.01.2015